Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Allogene Therapeutics has raised $200.4M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Allogene Therapeutics's investors include Franklin Templeton, TPG, Pfizer, Gilead Sciences, Perceptive Advisors.
Allogene Therapeutics is headquartered in South San Francisco, United States.
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Allogene Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allogene Therapeutics — Funding & Investors." VCBacked, April 14, 2026, https://www.vcbacked.co/company/allogene-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). Allogene Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/allogene-therapeutics
{{cite web |title=Allogene Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/allogene-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated